0001564590-22-014927.txt : 20220420 0001564590-22-014927.hdr.sgml : 20220420 20220420162032 ACCESSION NUMBER: 0001564590-22-014927 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220414 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220420 DATE AS OF CHANGE: 20220420 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TherapeuticsMD, Inc. CENTRAL INDEX KEY: 0000025743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870233535 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-00100 FILM NUMBER: 22838279 BUSINESS ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-961-1900 MAIL ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AMHN, Inc. DATE OF NAME CHANGE: 20090930 FORMER COMPANY: FORMER CONFORMED NAME: CROFF ENTERPRISES INC DATE OF NAME CHANGE: 19970915 FORMER COMPANY: FORMER CONFORMED NAME: CROFF OIL CO DATE OF NAME CHANGE: 19920703 8-K 1 txmd-8k_20220414.htm 8-K txmd-8k_20220414.htm
false 0000025743 0000025743 2022-04-14 2022-04-14

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 14, 2022

 

THERAPEUTICSMD, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada

 

001-00100

 

87-0233535

(State or Other

Jurisdiction of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

951 Yamato Road, Suite 220

Boca Raton, FL 33431

(Address of Principal Executive Office) (Zip Code)

 

Registrant’s telephone number, including area code:  (561) 961-1900

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share

TXMD

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


 

 

 

Item 2.01Completion of Acquisition or Disposition of Assets.

On April 14, 2022, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), completed the sale of all of the issued and outstanding capital stock (the “Divestiture”) of vitaCare Prescription Services, Inc., a Florida corporation and previously a wholly-owned subsidiary of the Company (“vitaCare”), to GoodRx, Inc. (“GoodRx”), a Delaware corporation and wholly-owned subsidiary of GoodRx Holdings, Inc., pursuant to that certain Stock Purchase Agreement, dated March 6, 2022, by and between the Company and GoodRx (the “Purchase Agreement”). As consideration for the Divestiture, GoodRx paid the Company approximately $150 million in cash, subject to adjustment as provided in the Purchase Agreement and customary holdbacks. In addition, the Purchase Agreement provides that the Company may receive up to an additional $7 million in earn-out consideration, contingent upon vitaCare’s financial performance through 2023, in accordance with the terms thereof.

The foregoing description of the Divestiture is not complete and is qualified in its entirety by the full text of the Purchase Agreement, which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 10, 2022 (the “Prior Report”) and is incorporated herein by reference.

Item 2.04

Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

As described in Prior Report, which is incorporated into this Item 2.04 by reference, the Company entered into Amendment No. 9 (the “Amendment”) to that certain Financing Agreement, dated as of April 24, 2019, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders from time to time party thereto (the “Lenders”), and certain of the Company’s subsidiaries party thereto from time to time as guarantors (the “Financing Agreement”).  Pursuant to the Amendment, the Company agreed to pay to the Lenders as a prepayment of the loans under the Financing Agreement the first $120 million of net proceeds from the Divestiture and all net proceeds of the Divestiture in excess of $135 million, and in connection with the closing of the Divestiture, the Company prepaid $120 million of the loans under the Financing Agreement on April 14, 2022 (the “Prepayment”).

The foregoing description of the Amendment is not complete and is qualified in its entirety by reference to the full text of the Amendment, which was filed as Exhibit 10.1 to the Prior Report and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(b)Pro forma financial information.

The unaudited pro forma condensed consolidated financial information of the Company giving effect to the Divestiture and the Prepayment is filed as Exhibit 99.1 hereto and incorporated herein by reference.

(d)Exhibits.

Exhibit Index

Exhibit No.

Description

 

 

 

 

99.1

Pro Forma Financial Statements with Respect to Disposition of vitaCare Prescription Services, Inc.

 

 

104

Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  April 20, 2022

 

THERAPEUTICSMD, INC.

 

 

 

 

 

 

/s/ Michael C. Donegan

 

 

Michael C. Donegan

 

 

Interim Chief Financial Officer, Chief Accounting Officer

and Vice President Finance

 

 

 EX-99.1 2 txmd-ex991_50.htm EX-99.1 txmd-ex991_50.htm

Exhibit 99.1

 

Unaudited Pro Forma Condensed Consolidated Financial Information

Overview

On April 14, 2022, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), pursuant to a stock purchase agreement (the “Purchase Agreement”), dated as of March 6, 2022, with GoodRx, Inc. (“GoodRx”), a Delaware corporation and previously a wholly-owned subsidiary of GoodRx Holdings, Inc., completed the divestiture of vitaCare Prescription Services, Inc., a Florida corporation and wholly-owned subsidiary of the Company (“vitaCare”), with the sale of all of the issued and outstanding capital stock of vitaCare to GoodRx. The transactions contemplated by the Purchase Agreement are referred to herein as the “Divestiture.” The purchase consideration was comprised of a cash payment of $150.0 million paid at closing, subject to certain escrow, minimum net working capital, and other adjustments. The Company received estimated proceeds of $129.4 million at closing, net of estimated transaction expenses of $8.3 million, certain escrow amounts of $11.25 million and working capital adjustments. The Company used $120.0 million of the net proceeds to repay part of the Company’s borrowings under that certain Financing Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders from time to time party thereto (the “Lenders”), and certain of the Company’s subsidiaries party thereto from time to time as guarantors (the “Financing Agreement”). The Company remains eligible to receive an additional $7.0 million in cash consideration for the Divestiture contingent on vitaCare’s financial performance through 2023 in accordance with the terms of the Purchase Agreement.

The Divestiture does not meet the criteria requiring discontinued operations presentation in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Divestiture is considered a disposition of a significant business under Item 2.01 of Form 8-K. As a result, the Company prepared the accompanying unaudited pro forma condensed consolidated financial statements included herein in accordance with Article 11 of Regulation S-X and based on historical financial information of the Company.

The accompanying unaudited pro forma condensed consolidated balance sheet gives effect to the Divestiture as if it had occurred on December 31, 2021, the end of the most recent period for which a balance sheet is required. The accompanying unaudited pro forma condensed consolidated statement of operations for year ended December 31, 2021 gives effect to the Divestiture as if it had occurred on January 1, 2021.

The accompanying unaudited pro forma condensed consolidated financial information includes pro forma adjustments that are directly attributable to the Divestiture and are factually supportable. Pro forma adjustments are presented for informational purposes only and are described in the accompanying notes based on information and assumptions currently available at the time of the filing of the Current Report on Form 8-K to which the unaudited pro forma condensed consolidated financial information is included as an exhibit (the “8-K”). The unaudited pro forma condensed consolidated financial information is not necessarily indicative of what the Company’s results of operations or financial condition would have been had the Divestiture been completed on the dates indicated above. In addition, it is not necessarily indicative of the Company’s future results of operations or financial condition and does not reflect all actions that have been or may be taken by the Company following the Divestiture.

The accompanying unaudited pro forma condensed consolidated financial information should be read in conjunction with the audited consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 10-K”).

 

 

 

TherapeuticsMD, Inc. and Subsidiaries

Unaudited Pro Forma Condensed Consolidated Balance Sheet

As of December 31, 2021

(In thousands except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Historical

 

 

Pro Forma

 

 

 

 

 

 

 

Financial

 

 

Adjustment

 

 

 

 

 

 

 

Statements

 

 

Related to

 

 

 

 

 

 

 

as Reported

 

 

Divestiture

 

 

Pro Forma

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

65,122

 

 

 

129,382

 

(a)

$

74,504

 

 

 

 

 

 

 

 

(120,000

)

(b)

 

 

 

Restricted cash

 

 

—

 

 

 

11,250

 

(c)

 

11,250

 

Accounts receivable, net of allowance for credit losses

 

 

36,176

 

 

 

(157

)

(d)

 

36,019

 

Inventory

 

 

7,622

 

 

 

 

 

 

 

7,622

 

Prepaid and other current assets

 

 

10,548

 

 

 

(16

)

(d)

 

10,532

 

Total current assets

 

 

119,468

 

 

 

 

 

 

 

139,927

 

Fixed assets, net

 

 

1,199

 

 

 

(157

)

(d)

 

1,042

 

License rights and other intangible assets, net

 

 

40,318

 

 

 

(36

)

(d)

 

40,282

 

Right of use assets

 

 

8,234

 

 

 

 

 

 

 

8,234

 

Other non-current assets

 

 

253

 

 

 

 

 

 

 

253

 

Total assets

 

$

169,472

 

 

 

 

 

 

$

189,738

 

Liabilities and stockholders' (deficit) equity:

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Current maturities of debt

 

$

188,269

 

 

 

(120,000

)

(b)

$

68,269

 

Accounts payable

 

 

20,318

 

 

 

(662

)

(d)

 

19,656

 

Accrued expenses and other current liabilities

 

 

44,304

 

 

 

(1,436

)

(d)

 

42,868

 

Total current liabilities

 

 

252,891

 

 

 

 

 

 

 

130,793

 

Operating lease liabilities, non-current

 

 

8,063

 

 

 

 

 

 

 

8,063

 

Other non-current liabilities

 

 

2,139

 

 

 

 

 

 

 

2,139

 

Total liabilities

 

 

263,093

 

 

 

 

 

 

 

140,995

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

Total stockholders' (deficit) equity

 

 

(93,621

)

 

 

142,364

 

(e)

 

48,743

 

Total liabilities and stockholders' (deficit) equity

 

$

169,472

 

 

 

 

 

 

$

189,738

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

 

2

 

 

TherapeuticsMD, Inc. and Subsidiaries

Unaudited Pro Forma Condensed Consolidated Statement of Operations

Year Ended December 31, 2021

(In thousands, except per share amounts)

 

 

 

Historical

 

 

Pro Forma

 

 

 

 

 

 

 

Financial

 

 

Adjustment

 

 

 

 

 

 

 

Statements

 

 

Related to

 

 

 

 

 

 

 

as Reported

 

 

Divestiture

 

 

Pro Forma

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue, net

 

$

85,780

 

 

 

(875

)

(f)

$

84,905

 

License revenue

 

 

1,171

 

 

 

 

 

 

 

1,171

 

Total revenue, net

 

 

86,951

 

 

 

 

 

 

 

86,076

 

Cost of goods sold

 

 

18,838

 

 

 

 

 

 

 

18,838

 

Gross profit

 

 

68,113

 

 

 

 

 

 

 

67,238

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling and marketing

 

 

108,195

 

 

 

(8,116

)

(f)

 

107,906

 

 

 

 

 

 

 

 

7,827

 

(g)

 

 

 

General and administrative

 

 

92,602

 

 

 

(14,141

)

(f)

 

78,461

 

Research and development

 

 

7,086

 

 

 

 

 

 

 

7,086

 

Total operating expenses

 

 

207,883

 

 

 

 

 

 

 

193,453

 

Loss from operations

 

 

(139,770

)

 

 

 

 

 

 

(126,215

)

Other (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense and other financing costs

 

 

(32,917

)

 

 

12,540

 

(h)

 

(20,377

)

Other income, net

 

 

272

 

 

 

142,364

 

(e)

 

142,636

 

Total other (expense) income

 

 

(32,645

)

 

 

 

 

 

 

122,259

 

Loss before income taxes

 

 

(172,415

)

 

 

 

 

 

 

(3,956

)

Provision for income taxes

 

 

—

 

 

 

 

 

 

 

—

 

Net loss

 

$

(172,415

)

 

 

 

 

 

$

(3,956

)

Loss per common share, basic and diluted

 

$

(0.43

)

 

 

 

 

 

$

(0.01

)

Weighted average common shares,

    basic and diluted

 

 

397,992

 

 

 

 

 

 

 

397,992

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

3

 

TherapeuticsMD, Inc. and Subsidiaries

Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements

1.

Basis of Pro Forma Presentation

The unaudited pro forma condensed consolidated financial information is based on the Company’s historical consolidated financial statements as adjusted to give effect to the transaction accounting adjustments in accordance with GAAP to reflect the Divestiture.

The Divestiture does not meet the criteria requiring discontinued operations presentation in accordance with U.S. GAAP. The Divestiture is considered a disposition of a significant business under Item 2.01 of Form 8-K. As a result, the Company prepared the unaudited pro forma condensed consolidated financial statements included herein, which were prepared in accordance with Article 11 of Regulation S-X and are based on historical financial information of the Company. The historical consolidated financial information has been adjusted in the accompanying unaudited pro forma condensed consolidated financial statements to give effect to pro forma events that are (i) directly attributable to the Divestiture and (ii) factually supportable. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.

The accompanying unaudited pro forma condensed consolidated financial information includes pro forma adjustments that are directly attributable to the Divestiture and are factually supportable. Pro forma adjustments are presented for informational purposes only and are described in the accompanying notes based on information and assumptions currently available at the time of the filing of the Current Report on Form 8-K with which unaudited pro forma condensed consolidated financial information is included as an exhibit. The unaudited pro forma condensed consolidated financial information is not necessarily indicative of what the Company’s results of operations or financial condition would have been had the Divestiture been completed on the dates indicated below. In addition, it is not necessarily indicative of the Company’s future results of operations or financial condition and does not reflect all actions that have been or may be taken by the Company following the Divestiture.

The accompanying unaudited pro forma condensed consolidated financial statements are based on the audited consolidated financial statements and accompanying notes included in the 2021 10-K . The unaudited pro forma condensed consolidated balance sheet as of December 31, 2021 gives effect to the Divestiture as if it had occurred on December 31, 2021. The unaudited pro forma condensed consolidated statement of operations for year ended December 31, 2021 gives effect to the Divestiture as if it had occurred on January 1, 2021.

2.

Pro Forma Adjustments

 

(a)

Adjustment reflects the estimated proceeds received, net of estimated transaction expenses of $8.3 million, certain escrow and working capital adjustments.

 

(b)

Adjustment reflects the use of cash proceeds to repay part of the Company’s borrowings under the Financing Agreement.

 

(c)

Adjustment reflects certain escrow funds netted from cash proceeds at closing and deposited into a restricted cash account held by a third-party financial institution. The escrow funds will be available to indemnify GoodRx pursuant to and in accordance with the terms of the Purchase Agreement.

 

(d)

Adjustment reflects the removal of the historical assets and liabilities of vitaCare.

 

(e)

Adjustment reflects the estimated gain attributable to the Divestiture.

 

(f)

Adjustment reflects the removal of the historical operations of vitaCare.

 

(g)

Adjustment reflects estimated service fees that would have been payable by the Company for certain pharmacy services performed by vitaCare if performed subsequent to the Divestiture.

 

(h)

Adjustment reflects the estimated decrease to interest expense from the partial repayment of the Company’s borrowings under the Financing Agreement.

 

4

 GRAPHIC 3 gw5lab3dx50z000001.jpg GRAPHIC begin 644 gw5lab3dx50z000001.jpg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end EX-101.SCH 4 txmd-20220414.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 txmd-20220414_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 txmd-20220414_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 14, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000025743
Document Type 8-K
Document Period End Date Apr. 14, 2022
Entity Registrant Name THERAPEUTICSMD, INC.
Entity Incorporation State Country Code NV
Entity File Number 001-00100
Entity Tax Identification Number 87-0233535
Entity Address, Address Line One 951 Yamato Road
Entity Address, Address Line Two Suite 220
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33431
City Area Code (561)
Local Phone Number 961-1900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol TXMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 txmd-8k_20220414_htm.xml IDEA: XBRL DOCUMENT 0000025743 2022-04-14 2022-04-14 false 0000025743 8-K 2022-04-14 THERAPEUTICSMD, INC. NV 001-00100 87-0233535 951 Yamato Road Suite 220 Boca Raton FL 33431 (561) 961-1900 false false false false Common Stock, par value $0.001 per share TXMD NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports txmd-8k_20220414.htm txmd-20220414.xsd txmd-20220414_lab.xml txmd-20220414_pre.xml txmd-ex991_50.htm gw5lab3dx50z000001.jpg http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "txmd-8k_20220414.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "txmd-8k_20220414.htm" ] }, "labelLink": { "local": [ "txmd-20220414_lab.xml" ] }, "presentationLink": { "local": [ "txmd-20220414_pre.xml" ] }, "schema": { "local": [ "txmd-20220414.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "txmd", "nsuri": "http://www.therapeuticsmd.com/20220414", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "txmd-8k_20220414.htm", "contextRef": "C_0000025743_20220414_20220414", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "txmd-8k_20220414.htm", "contextRef": "C_0000025743_20220414_20220414", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.therapeuticsmd.com/20220414/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-22-014927-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-014927-xbrl.zip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end